#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	7930	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2224	351.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	467	C,A,T	456,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14144	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3471	404.1	0	.	n	.	0	T695C	SNP	695	695	T	979	979	C	411	C	401	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14144	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3471	404.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1621	1621	A	443	A,G	423,11	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14144	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3471	404.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2255	2255	C	406	C	398	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14144	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3471	404.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2881	2881	T	436	T,C	418,18	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	14144	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3471	404.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2329	2329	A	461	A	455	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1064	folP	852	852	100.0	folP.l15.c4.ctg.1	1614	65.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1057	1059	AGC	122;122;123	A;G;C	121;121;118	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3032	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	86.3	1	SNP	p	S91F	0	.	.	271	273	TCC	639	641	TCC	92;93;94	T;C,T;C	91;91,2;93	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3032	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	86.3	1	SNP	p	D95N	0	.	.	283	285	GAC	651	653	GAC	96;94;96	G;A,G;C	95;90,2;95	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3032	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	86.3	1	SNP	p	D95G	0	.	.	283	285	GAC	651	653	GAC	96;94;96	G;A,G;C	95;90,2;95	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	892	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	67.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	458	460	ACC	99;100;99	A,G;C;C	93,2;99;96	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	892	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	67.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	473	475	CAC	100;99;101	C;A,G;C	97;92,3;100	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	892	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	67.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	656	658	CAC	115;115;115	C,T;A;C	108,6;110;112	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	892	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	67.3	1	SNP	p	G45D	0	.	.	133	135	GGC	476	478	GGC	101;102;102	G;G;C	100;101;99	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	576	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	996	56.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2550	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3004	84.3	1	SNP	p	D86N	0	.	.	256	258	GAC	615	617	GAC	105;104;105	G;A;C	104;100;105	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2550	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3004	84.3	1	SNP	p	S87I	0	.	.	259	261	AGT	618	620	AGT	106;106;106	A,C;G;T	98,5;104;103	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2550	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3004	84.3	1	SNP	p	S87W	0	.	.	259	261	AGT	618	620	AGT	106;106;106	A,C;G;T	98,5;104;103	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2550	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3004	84.3	1	SNP	p	S87R	0	.	.	259	261	AGT	618	620	AGT	106;106;106	A,C;G;T	98,5;104;103	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2550	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3004	84.3	1	SNP	p	S88P	0	.	.	262	264	TCC	621	623	TCC	105;106;105	T;C;C	105;105;103	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2076	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2864	71.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1627	1629	GGC	107;104;103	G;G;C	107;102;99	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1268	1270	GCA	106;109;112	G;C;A	102;105;111	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1271	1273	ATC	114;115;116	A;T;C	112;114;115	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1283	1285	GTG	115;113;114	G;T;G	112;109;109	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1283	1285	GTG	115;113;114	G;T;G	112;109;109	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1787	1789	ACC	94;95;95	A;C;C	93;93;93	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1841	1843	GCG	84;84;84	G;C,G;G	82;73,2;78	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1841	1843	GCG	84;84;84	G;C,G;G	82;73,2;78	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1964	1966	GGC	73;73;72	G;G;C,T	71;72;69,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1973	1975	GGC	64;63;63	G;G;C	61;61;61	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2030	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2373	84.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1991	1993	CCG	56;56;55	C;C;G,C	55;54;50,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	3092	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3207	95.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1726	1728	CTG	116;115;114	C;T,C;G	109;102,6;109	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1270	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1876	66.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	652	652	C	90	C	82	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	H217N	NONSYN	649	651	CAT	183	185	AAT	7;7;9	A;A;T	7;7;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	D218N	NONSYN	652	654	GAT	186	188	AAT	9;9;9	A;A;T	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	A222V	NONSYN	664	666	GCT	198	200	GTT	10;10;10	G;T;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	V226A	NONSYN	676	678	GTA	210	212	GCA	12;12;12	G;C;A	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	.	MULTIPLE	700	702	ACT	233	235	GTA	8;7;7	G;T;A	8;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	150	porB1a	984	309	91.05	porB1a.l15.c30.ctg.1	469	11.2	0	.	p	.	0	D238fs	FSHIFT	712	712	G	245	245	G	8	G	8	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	573	575	CTT	102;103;100	C,G,T;T;T,G	96,3,1;101;96,3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	597	599	GGA	107;105;107	G,C,A;G,A;A	104,2,1;101,4;103	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	735	737	AGC	106;105;106	A,G;G,A;C	102,4;104,1;106	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	801	801	T	107	T	102	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	1	SNP	p	G120K	0	.	.	358	360	GGT	528	530	GGT	101;101;101	G,A;G,A;T,G	98,2;98,2;97,2	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	1	SNP	p	A121D	0	.	.	361	363	GCC	531	533	GCC	100;100;100	G;C,A;C	100;96,2;98	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1456	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1365	103.4	1	SNP	p	A121N	0	.	.	361	363	GCC	531	533	GCC	100;100;100	G;C,A;C	100;96,2;98	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5100	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5113	99.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2073	2075	AAT	115;117;117	A,C;A;T	111,3;117;115	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	576	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1086	52.6	1	SNP	p	V57M	1	.	.	169	171	ATG	523	525	ATG	114;116;119	A;T;G	113;115;118	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
